Table 4.
Corneal antiangiogenesis target therapies91
| Targets | Methods | Therapeutics |
|---|---|---|
| Vascular endothelial growth factor | Anti-VEGF-A antibodies | Bevacizumab |
| Ranibizumab | ||
| FD006 | ||
| Soluble or modified VEGF receptors | Recombinant dimeric VEGFR-2-Fc | |
| sVEGFR-1 overexpression gene therapy | ||
| sVEGFR-3 overexpression gene therapy | ||
| VEGFR-1 morpholino | ||
| Aflibercept/VEGF-Trap(R1R2) | ||
| VEGFR intraceptor gene therapy | ||
| (Flt23k, Flt24k) | ||
| VEGF-A aptamer | Pegaptanib | |
| Pigment epithelium-derived factor | PEDF direct effect | PEDF |
| PEDF-derived peptide | ||
| PEDF gene therapy | ||
| Platelet-derived growth factor | PDGF receptor inhibitor | AG 1296 |
| Multitargeted receptor tyrosine | Sunitinib | |
| kinase inhibitor | ||
| Angiostatin | Angiostatin direct effect | Angiostatin pump |
| Hypoxia-inducible factors | shRNA for hypoxia-inducible factors | HIF-1α shRNA gene therapy (HIF- 1α RNAi-A) |
| 12-Hydroxyeicosatrienoic acid | siRNA for cytochrome P450 mono-oxygenase | CYP4B1 siRNA gene therapy |
| Vascular adhesion protein | VAP-1/SSAO inhibitor | U–V002 |
| LJP1207 | ||
| Decorin | Decorin direct effect | Decorin gene therapy |
| Vasohibin-1 | Vasohibin-1 directly effect | Vasohibin-1 gene therapy |
| Cannabinoid receptor CB1 | CB1 antagonist | Rimonabant |
CYP = cytochrome P450 mono-oxygenase; HIF-1α = hypoxia-inducible factor 1α; PDGF = platelet- derived growth factor; PEDF = pigment epithelium-derived factor; SSAO = semicarbazide-sensitive amine oxidase; sVEGFR = soluble form of vascular endothelial growth factor receptor; VAP- 1 = vascular adhesive protein-1; VEGF = vascular endothelial growth factor; VEGFR = vascular endothelial growth factor receptor.
Other potential therapies: steroid (dexamethasone, prednisolone, fluorometholone), rapamycin, cyclosporine A, thalidomide analogue (CC-3052). (Adapted from Hsu at el. with permission from Elsevier)